Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Avelumab + Trabectedin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Avelumab | Bavencio | MSB0010718C | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov). |
Trabectedin | Yondelis | ET-743 | Chemotherapy - Alkylating 18 | Yondelis (trabectedin) is a marine-derived alkaloid that binds to DNA and induces DNA strand breaks, leading to cell cycle arrest and cell death in tumor cells (PMID: 24755886). Yondelis (trabectedin) is FDA approved for metastatic liposarcoma or leiomyosarcoma who received prior anthracycline treatment (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03074318 | Phase Ib/II | Avelumab + Trabectedin | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |